| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1993;56:282-287
© 1993 The Society of Thoracic Surgeons
Section of Surgical Sciences, Department of Radiation Oncology, Division of Medical Oncology, and Thoracic Oncology Program, Vanderbilt University School of Medicine, Nashville, Tennessee USA
* Address reprint requests to Dr Stewart, Department of Cardiac and Thoracic Surgery, Rm 2986, The Vanderbilt Clinic, Nashville, TN 37232-5734.
Between December 1988 and August 1992, 68 patients with adenocarcinoma (n = 39) and squamous carcinoma (n = 29) of the esophagus were entered prospectively in a treatment protocol to receive two cycles of cisplatin, 5-fluorouracil, etoposide, leucovorin, and 3,000 cGy of radiation to the involved esophagus and adjacent mediastinum, followed by resection. There were four deaths during chemotherapy, and 7 patients had a decline in condition or were denied operation. Fifty-six patients have come to operation, and 1 awaits resection. Twentytwo patients had transhiatal esophagectomy and 29 patients had esophagogastrostomy with a combined abdominal and right thoracic approach. Five patients did not undergo resection at operation. There was one hospital death (2%). A complete response to preoperative therapy was seen in 12 patients (21%): 5 of 20 with squamous cancer (25%) and 7 of 36 with adenocarcinoma (19%). Average follow-up is 19 months. Median survival in these patients after entrance in the protocol is 24 months. Actuarial survival at 12, 18, and 24 months is 72% (confidence limits, 66% and 78%), 53% (confidence limits, 46% and 60%), and 51% (confidence limits, 44% and 58%). Significantly better survival was associated with adenocarcinoma (p = 0.041). There is no survival advantage based on complete response to preoperative therapy. This neoadjuvant regimen is effective in patients with squamous carcinoma and adenocarcinoma. These preliminary results demonstrate an improved median and actuarial survival compared with historical controls in 137 patients operated on between 1966 and 1985 at our institution.
This article has been cited by other articles:
|
|
 |
|
  H. Kato, A. Sato, H. Fukuda, Y. Kagami, H. Udagawa, A. Togo, N. Ando, O. Tanaka, M. Shinoda, H. Yamana, et al. A Phase II Trial of Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma: Japan Clinical Oncology Group Study (JCOG9708) Jpn. J. Clin. Oncol., October 1, 2009; 39(10): 638 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tachibana, S. Kinugasa, N. Hirahara, and H. Yoshimura Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma Eur J Cardiothorac Surg, August 1, 2008; 34(2): 427 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Lee, S. I. Park, S.-B. Kim, H.-Y. Jung, G. H. Lee, J.-H. Kim, H.-Y. Song, K.-J. Cho, W.-K. Kim, J.-S. Lee, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma Ann. Onc., June 1, 2004; 15(6): 947 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Avendano, P. A. Flume, G. A. Silvestri, L. B. King, and C. E. Reed Pulmonary complications after esophagectomy Ann. Thorac. Surg., March 1, 2002; 73(3): 922 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Lew, W. E. Gooding, U. Ribeiro Jr, A. V. Safatle-Ribeiro, and M. C. Posner Long-term Survival Following Induction Chemoradiotherapy and Esophagectomy for Esophageal Carcinoma Arch Surg, July 1, 2001; 136(7): 737 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yasunaga, Y. Tabira, K. Nakano, S. Iida, N. Ichimaru, N. Nagamoto, and T. Sakaguchi Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma Ann. Thorac. Surg., November 1, 2000; 70(5): 1634 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Hoff, J. L. Sawyers, C. D. Blanke, H. Choy, and J. R. Stewart Prognosis of Adenocarcinoma Arising in Barrett's Esophagus Ann. Thorac. Surg., January 1, 1998; 65(1): 176 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Jones, F. C. Detterbeck, T. M. Egan, L. A. Parker Jr, S. A. Bernard, and J. E. Tepper Induction Chemoradiotherapy Followed by Esophagectomy in Patients With Carcinoma of the Esophagus Ann. Thorac. Surg., July 1, 1997; 64(1): 185 - 192. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Kane III, L. L. Shears, U. Ribeiro, M. R. Clark, M. Peterson, R. J. Landreneau, and M. C. Posner Is Esophagectomy Following Upfront Chemoradiotherapy Safe and Necessary? Arch Surg, May 1, 1997; 132(5): 481 - 486. [Abstract] [PDF]
|
|
|
|
|
|
K. S. Naunheim, P. J. Petruska, T. S. Roy, J. M. Schlueter, H. Kim, and A. E. Baue Multimodality therapy for adenocarcinoma of the esophagus Ann. Thorac. Surg., May 1, 1995; 59(5): 1085 - 1091. [Abstract] [PDF]
|
|
|
|
|
|
C. D. Wright, D. J. Mathisen, J. C. Wain, H. C. Grillo, A. D. Hilgenberg, A. C. Moncure, R. W. Carey, N. C. Choi, M. Daly, and D. L. Logan Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction Ann. Thorac. Surg., December 1, 1994; 58(6): 1574 - 1579. [Abstract] [PDF]
|
|
|
|
|
|
J. S. McLaughlin Induction therapy for squamous carcinoma of the thoracic esophagus: The continuing journey Ann. Thorac. Surg., May 1, 1994; 57(5): 1064 - 1065. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
